<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2021-2-157-161</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-1555</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CONSENSUS OF EXPERT MEETING</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КОНСЕНСУС ЭКСПЕРТНОГО СОВЕЩАНИЯ</subject></subj-group></article-categories><title-group><article-title>COVID-19 vaccination guidelines for patients with multiple sclerosis</article-title><trans-title-group xml:lang="ru"><trans-title>Рекомендации по вакцинации пациентов с рассеянным склерозом от COVID-19</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хачанова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Khachanova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Россия, 117997, Москва, ул. Островитянова, 1 </p></bio><bio xml:lang="en"><p> 1, Ostrovityanov St., Moscow 117997, Russia </p><p> </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тотолян</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Totolyan</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Россия, 197022, Санкт-Петербург, ул. Льва Толстого, 6-8 </p></bio><bio xml:lang="en"><p> 6-8, Lev Tolstoy St., Saint Petersburg 197022, Russia </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Власов</surname><given-names>Я. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vlasov</surname><given-names>Ya. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 443099, Самара, ул. Чапаевская, 89; </p><p>Россия, 125167, Москва, Нарышкинская аллея, 5, стр. 2 </p></bio><bio xml:lang="en"><p> 89, Chapaevskaya St., Samara 443099, Russia;</p><p>5, Naryshkinskaya Alley, Build. 2, Moscow 125167, Russia </p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сиверцева</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sivertseva</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 625032, Тюмень, ул. Юрия Семовских, 8/1; </p><p>Россия, 123104, Москва, ул. М. Бронная, 16 </p></bio><bio xml:lang="en"><p> 8/1, Yuriya Semovskikh St., Tyumen 625032, Russia </p><p> 16, M. Bronnaya St., Moscow 123104, Russia </p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Давыдовская</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Davydovskaya</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Россия, 117997, Москва, ул. Островитянова, 1 </p><p> Россия, 190000, Санкт-Петербург, ул. Галерная, 20-22, лит. А </p></bio><bio xml:lang="en"><p> 1, Ostrovityanov St., Moscow 117997, Russia </p><p> 20-22, Galernaya St., Lit. A, Saint Petersburg 190000, Russia </p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Евдошенко</surname><given-names>Е. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Evdoshenko</surname><given-names>E. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Россия, 197110, Санкт-Петербург, пр. Динамо, 3 </p></bio><bio xml:lang="en"><p> 1, Dynamo Pr., Saint Petersburg 197110, Russia </p></bio><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Продеус</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Prodeus</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Россия, 123317, Москва, Шмитовский проезд, 29 </p></bio><bio xml:lang="en"><p> 29, Shmitovsky Proezd, Moscow 123317, Russia </p></bio><xref ref-type="aff" rid="aff-7"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Захарова</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Zakharova</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Россия, 125367, Москва, Волоколамское шоссе, 80 </p></bio><bio xml:lang="en"><p> 80, Volokolamskoe Shosse, Moscow 125367, Russia </p></bio><xref ref-type="aff" rid="aff-8"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Спирин</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Spirin</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Россия, 123104, Москва, ул. М. Бронная, 16 </p><p> Россия, 150000, Ярославль, ул. Революционная, 5 </p></bio><bio xml:lang="en"><p> 16, M. Bronnaya St., Moscow 123104, Russia </p><p> 5, Revolutsionnaya St., Yaroslavl 150000, Russia 150000 </p><p> </p><p> </p></bio><xref ref-type="aff" rid="aff-9"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бойко</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Boyko</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Россия, 117997, Москва, ул. Островитянова, 1 </p><p> Россия, 123104, Москва, ул. М. Бронная, 16 </p><p> Россия, 117997, Москва, ул. Островитянова, 1, стр. 10 </p></bio><bio xml:lang="en"><p> 1, Ostrovityanov St., Moscow 117997, Russia </p><p> 16, M. Bronnaya St., Moscow 123104, Russia </p><p> 1, Ostrovityanova St., Build. 10, Moscow 117997, Russia </p></bio><email xlink:type="simple">boykoan13@gmail.com</email><xref ref-type="aff" rid="aff-10"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кафедра неврологии, нейрохирургии и медицинской генетики ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of Neurology, Neurosurgery, and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>кафедра неврологии ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of Neurology, Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Кафедра неврологии и нейрохирургии ФГБОУ ВО «Самарский государственный медицинский университет»  Минздрава России;&#13;
Общероссийская общественная организация инвалидов-больных рассеянным склерозом (ОИИБРС)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of Neurology and Neurosurgery, Samara State Medical University, Ministry of Health of Russia;&#13;
All-Russian Public Organization of Disabled People with Multiple Sclerosis (PwMS RPO)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Тюменский областной центр рассеянного склероза, Тюмень;&#13;
Общероссийская общественная организация «Российский комитет исследователей рассеянного склероза» (РОКИРС)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tyumen Regional Center for Multiple Sclerosis;&#13;
All-Russian Public Organization «Russian Committee for Treatment and Research in Multiple Sclerosis (RUCTRIMS)»</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Кафедра неврологии, нейрохирургии и медицинской генетики ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России;&#13;
Медицинская ассоциация врачей и центров рассеянного склероза и других нейроиммунологических заболеваний (МАВРС)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of Neurology, Neurosurgery, and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia;&#13;
Medical Association of Physicians and Centers for Multiple Sclerosis and Other Neuroimmunological Diseasesеs (MAPMS)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>Санкт-Петербургский городской центр рассеянного склероза и других аутоиммунных заболеваний, ГБУЗ  «Городская клиническая больница №31»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Hospital Thirty-One, City Center for Multiple Sclerosis Treatment</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-7"><aff xml:lang="ru"><institution>ГБУЗ «Детская городская клиническая больница №9 им. Г.Н. Сперанского» Департамента здравоохранения г. Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>G.N. Speranskiy Children Hospital №9, Moscow Healthcare Department</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-8"><aff xml:lang="ru"><institution>6-е неврологическое отделение ФГБНУ «Научный центр неврологии» РАН</institution><country>Россия</country></aff><aff xml:lang="en"><institution>6th neurology unit, Research Center of Neurology, Ministry of Education and Science of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-9"><aff xml:lang="ru"><institution>Общероссийская общественная организация «Российский комитет исследователей рассеянного склероза» (РОКИРС);&#13;
кафедра нервных болезней с медицинской генетикой и нейрохирургией ФГБОУ ВО «Ярославский государственный медицинский университет»  Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>All-Russian Public Organization «Russian Committee for Treatment and Research in Multiple Sclerosis (RUCTRIMS)»;&#13;
Department of Neurology, Medical Genetics and Neurosurgery, Yaroslavl State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-10"><aff xml:lang="ru"><institution>Кафедра неврологии, нейрохирургии и медицинской генетики ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России;&#13;
Общероссийская общественная организация «Российский комитет исследователей рассеянного склероза» (РОКИРС);&#13;
Институт клинической неврологии ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА  России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Department of Neurology, Neurosurgery, and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia;&#13;
All-Russian Public Organization «Russian Committee for Treatment and Research in Multiple Sclerosis (RUCTRIMS)»;&#13;
Institute of Clinical Neurology, Federal Center for Brain and Neurotechnology, FMBA of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>25</day><month>04</month><year>2021</year></pub-date><volume>13</volume><issue>2</issue><fpage>157</fpage><lpage>161</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Khachanova N.V., Totolyan N.A., Vlasov Y.V., Sivertseva S.A., Davydovskaya M.V., Evdoshenko E.P., Prodeus A.P., Zakharova M.N., Spirin N.N., Boyko A.N., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Хачанова Н.В., Тотолян Н.А., Власов Я.В., Сиверцева С.А., Давыдовская М.В., Евдошенко Е.П., Продеус А.П., Захарова М.Н., Спирин Н.Н., Бойко А.Н.</copyright-holder><copyright-holder xml:lang="en">Khachanova N.V., Totolyan N.A., Vlasov Y.V., Sivertseva S.A., Davydovskaya M.V., Evdoshenko E.P., Prodeus A.P., Zakharova M.N., Spirin N.N., Boyko A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/1555">https://nnp.ima-press.net/nnp/article/view/1555</self-uri><abstract><p> The opinion of Russian experts on the possibility of COVID-19 vaccination in patients with multiple sclerosis (MS) is presented. The authors of the consensus, based on an analysis of a large number of domestic and foreign guidelines, conclude that it is possible to use killed and inactivated vaccines. Preliminary recommendations are given for COVID-19 vaccination, taking into account the MS disease modifying therapies. </p></abstract><trans-abstract xml:lang="ru"><p> Представлено мнение российских экспертов о возможности  проведения вакцинации против CОVID-19 больным рассеянным  склерозом (РС). Авторы консенсуса на основе анализа большого числа  отечественных и зарубежных рекомендаций делают вывод о  возможности проведения вакцинации убитыми и инактивированными  вакцинами. Даются предварительные рекомендации по проведению  прививок против CОVID-19 с учетом принимаемых пациентами  препаратов, изменяющих течение РС.  </p></trans-abstract><kwd-group xml:lang="ru"><kwd>рассеянный склероз</kwd><kwd>препараты</kwd><kwd>изменяющие течение рассеянного склероза</kwd><kwd>вакцинация против COVID-19</kwd><kwd>инфекции</kwd></kwd-group><kwd-group xml:lang="en"><kwd>multiple sclerosis</kwd><kwd>disease modifying therapies</kwd><kwd>COVID-19 vaccination</kwd><kwd>infections</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья опубликована при поддержке и участии Общероссийской общественной организации инвалидов-больных рассеянным склерозом (ОООИБРС)</funding-statement><funding-statement xml:lang="en">The article was published with the support and participation of All-Russian Public Organization of Disabled People with Multiple Sclerosis (PwMS RPO).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Гусев ЕИ, Мартынов МЮ, Бойко АН и др. Новая коронавирусная инфекция (COVID-19) и поражение нервной системы: механизмы неврологических расстройств, клинические проявления, организация неврологической помощи. Журнал неврологии и психиатрии им. С.С. Корсакова.</mixed-citation><mixed-citation xml:lang="en">Gusev EI, Martynov MYu, Boyko AN, et al. Novel coronavirus infection (COVID-19) and nervous system involvement: pathogenesis, clinical manifestations, organization of neurological care. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(6):7-16. doi: 10.17116/jnevro20201200617 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">;120(6):7-16 doi: 10.17116/jnevro20201200617</mixed-citation><mixed-citation xml:lang="en">Boyko AN, Sivertseva SA, Spirin NN. Nervous system damage in COVID-19 with an emphasis on the management of patients with multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(Suppl. 1):44-7. doi: 10.14412/2074-2711-2020-1S-44-47 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Бойко АН, Сиверцева СА, Спирин НН. Поражение нервной системы при инфекции COVID-19 с акцентом на ведение пациентов с рассеянным склерозом. Неврология, нейропсихиатрия, психосоматика. 2020;12(Прил. 1):44-7. doi: 10.14412/2074-2711-2020-1S-44-47</mixed-citation><mixed-citation xml:lang="en">Mares J, Hartung HP. Multiple sclerosis and COVID-19. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Sep;164(3):217-25. doi: 10.5507/bp.2020.033. Epub 2020 Jul 17.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mares J, Hartung HP. Multiple sclerosis and COVID-19. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Sep;164(3):217-25. doi: 10.5507/bp.2020.033. Epub 2020 Jul 17.</mixed-citation><mixed-citation xml:lang="en">Giovannoni G, Hawkes Ch, Lechner-Scott J, et al. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord. 2020 Apr;39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Giovannoni G, Hawkes Ch, Lechner-Scott J, et al. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord. 2020 Apr;39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.</mixed-citation><mixed-citation xml:lang="en">Louapre C, Collongues N, Stankoff B, et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020 Sep 1;77(9):1079-88. doi: 10.1001/jamaneurol.2020.2581</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Louapre C, Collongues N, Stankoff B, et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020 Sep 1;77(9):1079-88. doi: 10.1001/jamaneurol.2020.2581</mixed-citation><mixed-citation xml:lang="en">Zabalza A, Cardenas-Robledo S, Paula Tagliani P, et al. COVID-19 in multiple sclerosis patients: susceptibility, severity, risk factors and serological response. Eur J Neurol. 2020 Dec 19. doi: 10.1111/ene.14690. Online ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zabalza A, Cardenas-Robledo S, Paula Tagliani P, et al. COVID-19 in multiple sclerosis patients: susceptibility, severity, risk factors and serological response. Eur J Neurol. 2020 Dec 19. doi: 10.1111/ene.14690. Online ahead of print.</mixed-citation><mixed-citation xml:lang="en">The Canadian Network of MS Clinics (CNMSC) COVID-19 recommendations. Доступно по ссылке: https://mssociety.ca/library/document/5HYna7iVGyMLIT8moZNpw6K30PhzuWAc/original.pdf (дата обращения 15.03.2021).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">The Canadian Network of MS Clinics (CNMSC) COVID-19 recommendations. Доступно по ссылке: https://mssociety.ca/library/document/5HYna7iVGyMLIT8moZNpw6K30PhzuWAc/original.pdf (дата обращения 15.03.2021).</mixed-citation><mixed-citation xml:lang="en">National MS Society. COVID-19 vaccine guidance for people living with MS. Доступно по ссылке: https://www.nationalmssociety.org/coronaviruscovid-19-information/multiple-sclerosis-andcoronavirus/covid-19-vaccine-guidance#section-1 (дата обращения 15.03.2021).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">National MS Society. COVID-19 vaccine guidance for people living with MS. Доступно по ссылке: https://www.nationalmssociety.org/coronaviruscovid-19-information/multiple-sclerosis-andcoronavirus/covid-19-vaccine-guidance#section-1 (дата обращения 15.03.2021).</mixed-citation><mixed-citation xml:lang="en">Barts MS. SARS-CoV2 vaccine advice for people with Multiple Sclerosis. Доступно по ссылке: https://multiple-sclerosisresearch.org/2021/01/bartsms-covid-19-vaccineadvice-update/ (дата обращения 15.03.2021).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Barts MS. SARS-CoV2 vaccine advice for people with Multiple Sclerosis. Доступно по ссылке: https://multiple-sclerosisresearch.org/2021/01/bartsms-covid-19-vaccineadvice-update/ (дата обращения 15.03.2021).</mixed-citation><mixed-citation xml:lang="en">MS International Federation. Global COVID-19 advice for people with MS. Доступно по ссылке: https://www.msif.org/news/2020/02/10/thecoronavirus-and-ms-what-you-need-to-know/ (дата обращения 15.03.2021).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">MS International Federation. Global COVID-19 advice for people with MS. Доступно по ссылке: https://www.msif.org/news/2020/02/10/thecoronavirus-and-ms-what-you-need-to-know/ (дата обращения 15.03.2021).</mixed-citation><mixed-citation xml:lang="en">MS Society Medical Advisers consensus statement on MS treatment. Доступно по ссылке: https://www.mssociety.org.uk/whatwe-do/news/ms-society-medical-advisersrelease-consensus-statement-covid-19-vaccines (дата обращения 15.03.2021).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">MS Society Medical Advisers consensus statement on MS treatment. Доступно по ссылке: https://www.mssociety.org.uk/whatwe-do/news/ms-society-medical-advisersrelease-consensus-statement-covid-19-vaccines (дата обращения 15.03.2021).</mixed-citation><mixed-citation xml:lang="en">Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata «EpiVakKorona vaktsina na osnove peptidnykh antigenov dlya profilaktiki COVID-19». LP-006504-131020 [Instructions for the medical use of the drug «EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19». LP-006504-131020]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3d79aeab-fdb0-4979-816af5732691fc34&amp;t (accessed 15.03.2021) (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Инструкция по медицинскому применению лекарственного препарата «ЭпиВакКорона вакцина на основе пептидных антигенов для профилактики COVID-19». ЛП-006504-131020. Доступно по ссылке: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3d79aeab-fdb0-4979-816a-f5732691fc34&amp;t (дата обращения 15.03.2021).</mixed-citation><mixed-citation xml:lang="en">Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata «Gam-Kovid-Vak-Lio kombinirovannaya vektornaya vaktsina dlya profilaktiki koronavirusnoy infektsii, vyzyvayemoy virusom SARS-CoV-2». LP-006423-250820 [Instructions for the medical use of the drug «Gam-Covid-Vac-Lyo combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus.» LP-006423-250820]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=be951906-cc2c-40ff-af19-30edb36c68ad&amp;t (accessed 15.03.2021) (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Инструкция по медицинскому применению лекарственного препарата «Гам-Ковид-Вак-Лио комбинированная векторная вакцина для профилактики коронавирусной инфекции, вызываемой вирусом SARS-CoV-2». ЛП-006423-250820. Доступно по ссылке: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=be951906-cc2c-40ff-af19-30edb36c68ad&amp;t (дата обращения 15.03.2021).</mixed-citation><mixed-citation xml:lang="en">Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata «Gam-KOVID-Vak Kombinirovannaya vektornaya vaktsina dlya profilaktiki koronavirusnoy infektsii, vyzyvayemoy virusom SARS-CoV-2». LP-006395-231020 [Instructions for the medical use of the drug «Gam-COVID-Vac Combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus». LP-006395-231020]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=be951906-cc2c-40ff-af19-30edb36c68ad&amp;t (accessed 15.03.2021) (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Инструкция по медицинскому применению лекарственного препарата «Гам-КОВИД-Вак Комбинированная векторная вакцина для профилактики коронавирусной инфекции, вызываемой вирусом SARS-CoV-2». ЛП-006395-231020. Доступно по ссылке: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=be951906-cc2c-40ff-af19-30edb36c68ad&amp;t (дата обращения 15.03.2021).</mixed-citation><mixed-citation xml:lang="en">Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata «KoviVak vaktsina koronavirusnaya inaktivirovannaya tsel'novirionnaya kontsentrrovannaya ochishchennaya». LP-006800-190221 [Instructions for medical use of the drug «KoviVak vaccine coronavirus inactivated whole virion concentrated purified». LP-006800-190221]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspxroutingGuid=71035dbe-6178-42c0-8d36-aa54e546a65b&amp;t (accessed 15.03.2021) (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Инструкция по медицинскому применению лекарственного препарата «КовиВак вакцина коронавирусная инактивированная цельновирионная концентррованная очищенная». ЛП-006800-190221. Доступно по ссылке: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=</mixed-citation><mixed-citation xml:lang="en">Vremennyye metodicheskiye rekomendatsii «Profilaktika, diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID-19)». Ministerstvo zdravookhraneniya Rossiyskoy Federatsii. Versiya 10 ot 08.02.2021 [Interim guidelines «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)». Ministry of Health of the Russian Federation. Version 10 dated 02/08/2021]. Available from: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/588/original/%D0%92%D1%80%D0%B5%D0%BC%D0%B5%D0%BD%D0%BD%D1%8B%D0%B5_%D0%9C%D0%A0_COVID-19_%28v.10%29-08.02.2021_%281%29.pdf (accessed 15.03.2021) (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">dbe-6178-42c0-8d36-aa54e546a65b&amp;t (дата обращения 15.03.2021).</mixed-citation><mixed-citation xml:lang="en">Reyes S, Ramsay M, Ladhani S, et al. Protecting people with multiple sclerosis through vaccination. Pract Neurol. 2020 Dec;20(6):435-45. doi: 10.1136/practneurol-2020-002527. Epub 2020 Jul 6.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции</mixed-citation><mixed-citation xml:lang="en">Farez M, Correale J, Armstrong MJ, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2019 Sep 24;93(13):584-94. doi: 10.1212/WNL.0000000000008157. Epub 2019 Aug 28.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">(COVID-19)». Министерство здравоохранения Российской Федерации. Версия 10 от 08.02.2021. Доступно по ссылке: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/588/original/%D0%92%D1%80%D0%B5%D0%BC%D0%B5%D0%BD%D0%BD%D1%8B%D0%B5_%D0%9C%D0%A0_COVID-19_%28v.10%29-08.02.2021_%281%29.pdf (дата обращения 15.03.2021).</mixed-citation><mixed-citation xml:lang="en">Zrzavy T, Kollaritsch H, Rommer PS, et al. Vaccination in Multiple Sclerosis: Friend or Foe? Front Immunol. 2019 Aug 7;10:1883. doi: 10.3389/fimmu.2019.01883. eCollection 2019.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Reyes S, Ramsay M, Ladhani S, et al. Protecting people with multiple sclerosis through vaccination. Pract Neurol. 2020 Dec;20(6):435-45. doi: 10.1136/practneurol-2020-002527. Epub 2020 Jul 6.</mixed-citation><mixed-citation xml:lang="en">Lebrun C, Vukusic S. Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society. Mult Scler Relat Disord. 2019 Jun;31:173-88. doi: 10.1016/j.msard.2019.04.004. Epub 2019 Apr 10.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Farez M, Correale J, Armstrong MJ, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2019 Sep 24;93(13):584-94. doi: 10.1212/WNL.0000000000008157. Epub 2019 Aug 28.</mixed-citation><mixed-citation xml:lang="en">Bar-Or A, Freedman MS, Kremenchutzky M, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013 Aug 6;81(6):552-8. doi: 10.1212/WNL.0b013e31829e6fbf. Epub 2013 Jul 12.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Zrzavy T, Kollaritsch H, Rommer PS, et al. Vaccination in Multiple Sclerosis: Friend or Foe? Front Immunol. 2019 Aug 7;10:1883. doi: 10.3389/fimmu.2019.01883. eCollection 2019.</mixed-citation><mixed-citation xml:lang="en">Von Hehn C, Howard J, Liu S, et al. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2017 Nov 15;5(1):e409. doi: 10.1212/NXI.0000000000000409. eCollection 2018 Jan.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lebrun C, Vukusic S. Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society. Mult Scler Relat Disord. 2019 Jun;31:173-88. doi: 10.1016/j.msard.2019.04.004. Epub 2019 Apr 10.</mixed-citation><mixed-citation xml:lang="en">Kaufman M, Pardo G, Rossman H, et al. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014 Jun 15;341(1-2):22-7. doi: 10.1016/j.jns.2014.03.035. Epub 2014 Mar 26.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Bar-Or A, Freedman MS, Kremenchutzky M, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013 Aug 6;81(6):552-8. doi: 10.1212/WNL.0b013e31829e6fbf. Epub 2013 Jul 12.</mixed-citation><mixed-citation xml:lang="en">Kappos L, Mehling M, Arroyo R, et al. Randomized trial of vaccination in fingolimodtreated patients with multiple sclerosis. Neurology. 2015 Mar 3;84(9):872-9. doi: 10.1212/WNL.0000000000001302. Epub 2015 Jan 30.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Von Hehn C, Howard J, Liu S, et al. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2017 Nov 15;5(1):e409. doi: 10.1212/NXI.0000000000000409. eCollection 2018 Jan.</mixed-citation><mixed-citation xml:lang="en">McCarthy CL, Tuohy O, Compston DAS, et al. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013 Sep 3;81(10):872-6. doi: 10.1212/WNL.0b013e3182a35215. Epub 2013 Aug 7.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kaufman M, Pardo G, Rossman H, et al. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014 Jun 15;341(1-2):22-7. doi: 10.1016/j.jns.2014.03.035. Epub 2014 Mar 26.</mixed-citation><mixed-citation xml:lang="en">Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology. 2020;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kappos L, Mehling M, Arroyo R, et al. Randomized trial of vaccination in fingolimodtreated patients with multiple sclerosis. Neurology. 2015 Mar 3;84(9):872-9. doi: 10.1212/WNL.0000000000001302. Epub 2015 Jan 30.</mixed-citation><mixed-citation xml:lang="en">Zheng C, Kar I, Kaori Chen C, et al. Multiple Sclerosis DiseaseModifying Therapy and the COVID19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs. 2020 Sep;34(9):879-96. doi: 10.1007/s40263-020-00756-y</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">McCarthy CL, Tuohy O, Compston DAS, et al. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013 Sep 3;81(10):872-6. doi: 10.1212/WNL.0b013e3182a35215. Epub 2013 Aug 7.</mixed-citation><mixed-citation xml:lang="en">Otero-Romero S, Rodriguez-Garcia J, Vilella A, et al. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement. Neurologia. Jan-Feb 2021;36(1):50-60. doi: 10.1016/j.nrl.2020.02.006. Epub 2020 Jun 17.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology. 2020;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380</mixed-citation><mixed-citation xml:lang="en">Sellner J, Rommer PS. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines (Basel). 2021 Jan 28;9(2):99. doi: 10.3390/vaccines9020099</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng C, Kar I, Kaori Chen C, et al. Multiple Sclerosis DiseaseModifying Therapy and the COVID19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs. 2020 Sep;34(9):879-96. doi: 10.1007/s40263-020-00756-y</mixed-citation><mixed-citation xml:lang="en">Ciotti J, Valtcheva M, Cross A. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord. 2020 Oct;45:102439. doi: 10.1016/j.msard.2020.102439. Epub 2020 Aug 1.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Otero-Romero S, Rodriguez-Garcia J, Vilella A, et al. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement. Neurologia. Jan-Feb 2021;36(1):50-60.</mixed-citation><mixed-citation xml:lang="en">Otero-Romero S, Rodriguez-Garcia J, Vilella A, et al. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement. Neurologia. Jan-Feb 2021;36(1):50-60.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">doi: 10.1016/j.nrl.2020.02.006. Epub 2020 Jun 17.</mixed-citation><mixed-citation xml:lang="en">doi: 10.1016/j.nrl.2020.02.006. Epub 2020 Jun 17.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Sellner J, Rommer PS. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines (Basel). 2021 Jan 28;9(2):99. doi: 10.3390/vaccines9020099</mixed-citation><mixed-citation xml:lang="en">Sellner J, Rommer PS. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines (Basel). 2021 Jan 28;9(2):99. doi: 10.3390/vaccines9020099</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Ciotti J, Valtcheva M, Cross A. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord. 2020 Oct;45:102439. doi: 10.1016/j.msard.2020.102439. Epub 2020 Aug 1.</mixed-citation><mixed-citation xml:lang="en">Ciotti J, Valtcheva M, Cross A. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord. 2020 Oct;45:102439. doi: 10.1016/j.msard.2020.102439. Epub 2020 Aug 1.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
